Table 4.
Outcomes in patients with PC from CRC treated with CRS and HIPEC or Early Postoperative Intraperitoneal Chemotherapy.
| Study | Year | No of patients | Perfusion agent, dose, length, t° | Median OS (months), (resection status) |
|---|---|---|---|---|
| Glehen et al. [10] | 2004 | 53 23 |
MMC: 40-60 mg at 46-48°C for 90 min | 13 (all patients) 33 (CC-0) |
| Glehen et al. [11] | 2004 | 506 271 106 |
(1) MMC (30/50 mg/m2) ± cisplatin (50-100 mg/m2) at 41-42.5 °C for 60-120 min (2) oxaliplatin (360-460 mg/m2) ± irinoteacan (100-200 mg/m2) ± IV 5-FU + leucovorin at 43 °C for 30 min |
19 (all patients) 32 (CC-0) 24 (CC-1) |
| Elias et al. [12] | 2010 |
523 439 |
(1) MMC (30/50 mg/m2) ± cisplatin (50-100 mg/m2) at 41°C for 60-120 min (2) oxaliplatin (360-460 mg/m2) ± irinoteacan (200 mg/m2) ± IV 5-FU + leucovorin at 43 °C for 30 min |
30 (all patients) 33 (CC-0) |
| Verwaal et al. [13] | 2008 |
54 |
MMC: initial dose of 17.5 mg/m2 with additional 8.8 mg/m2 every 30 min (maximal dose in total 70 mg/m2)at 41-42 °C for 90 min | 22 (all patients) 48 (R-1) |
| Franko et al. [14] | 2010 |
67 |
MMC: initial dose of 30 mg for 60 min with additional 10 mg after for 40 min | 35 (all patients) |
| ASPSM study [15] | 2014 |
392 |
MMC: initial dose of 30 mg with additional 10 mg in 60 min at 42°C for 90 minutes | 33 (CC-0/1) |
| This study | 2018 | 19 29 |
Melphalan MMC |
36 (CC-0/1) 28 (CC-0/1) |
MMC: mitomycin-C; OS: overall survival; R-0: no gross disease with negative resection margins, R-1: no gross disease with positive resection margins; CC-0: no visible residual disease; CC-1: residual disease <2mm;